Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label trial of two depigmented modified house dust mite allergen mixtures in allergic rhinitis/rhinoconjunctivitis with controlled asthma
2014-000172-26Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- May 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dermatophagoides pteronyssinus + blomia tropicalis depigmented modified allergen extract and dermatophagoides pteronyssinus + lepidoglyphus destructor depigmented modified allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma and 1 more (2 arms), sponsored by LETI Pharma. Primary endpoint: Primary safety endpoint. Started May 2014; status: completed.
02
Drugs
dermatophagoides pteronyssinus + blomia tropicalis depigmented modified allergen extractdermatophagoides pteronyssinus + lepidoglyphus destructor depigmented modified allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthmahouse dust mite allergy
Beyond the preview
Go deeper on 2014-000172-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000172-26.